CD8A and neoplasm: Consistently, we observed that long-term Anlotinib treatments at the dose of 2 mg/kg, but not 8 mg/kg, reduced the levels of PD-L1 expression in tumor endothelial cells compared with control tumor blood vessels (Supplementary Figure S5), which may contribute to the increased tumor infiltration of CD8+ T cells upon Anlotinib treatments.